A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients
Abstract Olanzapine has exhibited efficacy as an antiemetic agent when used with 5-HT3 receptor antagonists, dexamethasone, and NK1 receptor antagonists for patients receiving highly emetogenic chemotherapy. In addition, several studies have reported the efficacy or safety of olanzapine in patients...
Guardado en:
| Autores principales: | , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Nature Portfolio
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/a96bf649e84c4db8abb0c8667118f623 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:a96bf649e84c4db8abb0c8667118f623 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:a96bf649e84c4db8abb0c8667118f6232021-12-02T15:54:14ZA phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients10.1038/s41598-021-84225-62045-2322https://doaj.org/article/a96bf649e84c4db8abb0c8667118f6232021-02-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-84225-6https://doaj.org/toc/2045-2322Abstract Olanzapine has exhibited efficacy as an antiemetic agent when used with 5-HT3 receptor antagonists, dexamethasone, and NK1 receptor antagonists for patients receiving highly emetogenic chemotherapy. In addition, several studies have reported the efficacy or safety of olanzapine in patients receiving moderately emetogenic chemotherapy, including carboplatin, irinotecan, and oxaliplatin. However, no reports of olanzapine use have focused on patients receiving oxaliplatin-based chemotherapy. Therefore, we analyzed the safety of antiemetic therapy using olanzapine, palonosetron, aprepitant, and dexamethasone in colorectal cancer patients undergoing oxaliplatin-based chemotherapy. This study was a prospective phase II single-institution study of 40 patients (median age 60 years, 23 patients were male). The primary endpoint was the incidence of adverse events, and the exploratory endpoints were the rate of chemotherapy-induced nausea and vomiting. Almost all patients (90%) had a performance status of 0. All patients received the scheduled antiemetic therapy. The most common adverse event was somnolence (n = 7 patients, 17.5%). All adverse events were grade 1. Thirty-six patients were included in the exploratory analysis of efficacy. No patients experienced vomiting during the first 120 h after chemotherapy, and complete response and complete control were both 86.1%. The rate of total control was 55.6% during the same time period. Olanzapine use with 5-HT3 receptor antagonists, dexamethasone, and NK1 receptor antagonists was safe for colorectal cancer patients receiving oxaliplatin-based chemotherapy.Junichi NishimuraAkiko HasegawaToshihiro KudoTomoyuki OtsukaMasayoshi YasuiChu MatsudaNaotsugu HaraguchiHajime UshigomeNozomu NakaiTomoki AbeHisashi HaraNaoki ShinnoKei AsukaiShinichiro HasegawaDaisaku YamadaKeijiro SugimuraKazuyoshi YamamotoHiroshi WadaHidenori TakahashiTakeshi OmoriHiroshi MiyataMasayuki OhueNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-6 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Medicine R Science Q |
| spellingShingle |
Medicine R Science Q Junichi Nishimura Akiko Hasegawa Toshihiro Kudo Tomoyuki Otsuka Masayoshi Yasui Chu Matsuda Naotsugu Haraguchi Hajime Ushigome Nozomu Nakai Tomoki Abe Hisashi Hara Naoki Shinno Kei Asukai Shinichiro Hasegawa Daisaku Yamada Keijiro Sugimura Kazuyoshi Yamamoto Hiroshi Wada Hidenori Takahashi Takeshi Omori Hiroshi Miyata Masayuki Ohue A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients |
| description |
Abstract Olanzapine has exhibited efficacy as an antiemetic agent when used with 5-HT3 receptor antagonists, dexamethasone, and NK1 receptor antagonists for patients receiving highly emetogenic chemotherapy. In addition, several studies have reported the efficacy or safety of olanzapine in patients receiving moderately emetogenic chemotherapy, including carboplatin, irinotecan, and oxaliplatin. However, no reports of olanzapine use have focused on patients receiving oxaliplatin-based chemotherapy. Therefore, we analyzed the safety of antiemetic therapy using olanzapine, palonosetron, aprepitant, and dexamethasone in colorectal cancer patients undergoing oxaliplatin-based chemotherapy. This study was a prospective phase II single-institution study of 40 patients (median age 60 years, 23 patients were male). The primary endpoint was the incidence of adverse events, and the exploratory endpoints were the rate of chemotherapy-induced nausea and vomiting. Almost all patients (90%) had a performance status of 0. All patients received the scheduled antiemetic therapy. The most common adverse event was somnolence (n = 7 patients, 17.5%). All adverse events were grade 1. Thirty-six patients were included in the exploratory analysis of efficacy. No patients experienced vomiting during the first 120 h after chemotherapy, and complete response and complete control were both 86.1%. The rate of total control was 55.6% during the same time period. Olanzapine use with 5-HT3 receptor antagonists, dexamethasone, and NK1 receptor antagonists was safe for colorectal cancer patients receiving oxaliplatin-based chemotherapy. |
| format |
article |
| author |
Junichi Nishimura Akiko Hasegawa Toshihiro Kudo Tomoyuki Otsuka Masayoshi Yasui Chu Matsuda Naotsugu Haraguchi Hajime Ushigome Nozomu Nakai Tomoki Abe Hisashi Hara Naoki Shinno Kei Asukai Shinichiro Hasegawa Daisaku Yamada Keijiro Sugimura Kazuyoshi Yamamoto Hiroshi Wada Hidenori Takahashi Takeshi Omori Hiroshi Miyata Masayuki Ohue |
| author_facet |
Junichi Nishimura Akiko Hasegawa Toshihiro Kudo Tomoyuki Otsuka Masayoshi Yasui Chu Matsuda Naotsugu Haraguchi Hajime Ushigome Nozomu Nakai Tomoki Abe Hisashi Hara Naoki Shinno Kei Asukai Shinichiro Hasegawa Daisaku Yamada Keijiro Sugimura Kazuyoshi Yamamoto Hiroshi Wada Hidenori Takahashi Takeshi Omori Hiroshi Miyata Masayuki Ohue |
| author_sort |
Junichi Nishimura |
| title |
A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients |
| title_short |
A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients |
| title_full |
A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients |
| title_fullStr |
A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients |
| title_full_unstemmed |
A phase II study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients |
| title_sort |
phase ii study of the safety of olanzapine for oxaliplatin based chemotherapy in coloraectal patients |
| publisher |
Nature Portfolio |
| publishDate |
2021 |
| url |
https://doaj.org/article/a96bf649e84c4db8abb0c8667118f623 |
| work_keys_str_mv |
AT junichinishimura aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT akikohasegawa aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT toshihirokudo aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT tomoyukiotsuka aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT masayoshiyasui aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT chumatsuda aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT naotsuguharaguchi aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT hajimeushigome aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT nozomunakai aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT tomokiabe aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT hisashihara aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT naokishinno aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT keiasukai aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT shinichirohasegawa aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT daisakuyamada aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT keijirosugimura aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT kazuyoshiyamamoto aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT hiroshiwada aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT hidenoritakahashi aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT takeshiomori aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT hiroshimiyata aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT masayukiohue aphaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT junichinishimura phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT akikohasegawa phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT toshihirokudo phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT tomoyukiotsuka phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT masayoshiyasui phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT chumatsuda phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT naotsuguharaguchi phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT hajimeushigome phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT nozomunakai phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT tomokiabe phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT hisashihara phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT naokishinno phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT keiasukai phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT shinichirohasegawa phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT daisakuyamada phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT keijirosugimura phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT kazuyoshiyamamoto phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT hiroshiwada phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT hidenoritakahashi phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT takeshiomori phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT hiroshimiyata phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients AT masayukiohue phaseiistudyofthesafetyofolanzapineforoxaliplatinbasedchemotherapyincoloraectalpatients |
| _version_ |
1718385468854239232 |